PNA forms new partnership with the Mayo Clinic Epilepsy Division. Read more

---

Phoenix Neurological Associates, LTD was just named one of seven international centers of Excellence for Guillan Barre and CIDP. Read more

Subcutaneous Injection of Interferon Beta-1a in RRMS

Trial Status
Open for Enrollment

What is the Purpose of this Study?
Evaluate efficacy and safety of a new interferon beta-1a in subjects with Relapsing MS

Who is Eligible?
Patients 18 to 55 with 2 relapses within the past 3 years with at least on relapse in the last 12 months. Further inclusion and exclusion criteria will be explained in detail by the study coordinator

What is involved in this Study?
All subjects will receive self administered subcutaneous injections of study treatment or placebo every 2 weeks. Patients will come to the clinic for exams and other study related procedures.

How long is the Study?
The study is approximately 2 years long

For more information contact: Lynne E. Flynn, CCRC, study coordinator, at 602-258-2863 or lynneflynn@pnal.net